ARVINAS, INC. (ARVN) Current Ratio
- Current ratio · latest quarter: Value 7.91×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 7.91× | Current assets / current liabilities. $652.20M ÷ $82.50M ≈ 7.91× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 652.20M USD | Assets, Current |
| Current obligations | 82.50M USD | Liabilities, Current |
| Cash and equivalents | 94.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 473.60M USD | Marketable Securities, Current |
| Customer receivables | 50.30M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 7.50M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 200.00K USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $652.20M | $82.50M | $94.30M | $473.60M | $50.30M | (m) | $7.50M | $200.00K | 7.91× |
| 2026-03-31 | $630.70M | $115.90M | $87.30M | $527.60M | $1.80M | (m) | $31.40M | $200.00K | 5.44× |
| 2025-12-31 | $700.70M | $142.50M | $142.90M | $542.50M | $1.00M | (m) | $24.40M | $200.00K | 4.92× |
| 2025-09-30 | $826.30M | $144.90M | $101.50M | $686.10M | $20.30M | (m) | $18.00M | $200.00K | 5.70× |
| 2025-06-30 | $889.50M | $157.80M | $114.90M | $746.30M | $500.00K | (m) | $16.60M | $200.00K | 5.64× |
| 2025-03-31 | $979.70M | $214.00M | $81.00M | $873.30M | $400.00K | (m) | $26.40M | $200.00K | 4.58× |
| 2024-12-31 | $1.07B | $229.80M | $100.50M | $938.90M | $5.70M | (m) | $13.40M | $200.00K | 4.64× |
| 2024-09-30 | $1.15B | $275.90M | $85.20M | $1.04B | $7.30M | (m) | $17.70M | $200.00K | 4.17× |
| 2024-06-30 | $1.26B | $347.20M | $154.80M | $1.07B | $1.80M | (m) | $23.20M | $200.00K | 3.62× |
| 2024-03-31 | $1.19B | $240.80M | $88.00M | $1.08B | $0.00 | (m) | $17.80M | $200.00K | 4.94× |
| 2023-12-31 | $1.28B | $257.10M | $311.70M | $949.30M | $0.00 | (m) | $17.80M | $200.00K | 4.98× |
| 2023-09-30 | $1.03B | $317.30M | $113.70M | $884.80M | $15.70M | (m) | $34.30M | $200.00K | 3.26× |
| 2023-06-30 | $1.06B | $306.90M | $90.60M | $948.20M | $100.00K | (m) | $6.70M | $100.00K | 3.44× |
| 2023-03-31 | $1.15B | $282.90M | $130.20M | $993.30M | $0.00 | (m) | $12.30M | $100.00K | 4.06× |
| 2022-12-31 | $1.24B | $295.10M | $81.30M | $1.12B | $1.00M | (m) | $5.70M | $0.00 | 4.20× |
| 2022-09-30 | $1.30B | $244.60M | $132.60M | $1.14B | $1.00M | (m) | $7.90M | (m) | 5.33× |
| 2022-06-30 | $1.38B | $238.20M | $93.20M | $1.25B | $1.40M | (m) | $12.30M | (m) | 5.78× |
| 2022-03-31 | $1.46B | $238.00M | $62.30M | $1.37B | $0.00 | (m) | $8.60M | (m) | 6.12× |
| 2021-12-31 | $1.55B | $261.70M | $108.30M | $1.39B | $15.00M | (m) | $31.30M | (m) | 5.93× |
| 2021-09-30 | $1.58B | $182.51M | $255.66M | $1.29B | $1.88M | (m) | $4.67M | (m) | 8.64× |
| 2021-06-30 | $627.73M | $41.82M | $48.73M | $551.85M | (m) | (m) | $4.98M | (m) | 15.01× |
| 2021-03-31 | $664.66M | $40.37M | $346.07M | $305.20M | (m) | (m) | $9.00M | (m) | 16.46× |
| 2020-12-31 | $703.10M | $49.20M | $588.40M | $100.20M | $1.00M | (m) | $7.10M | (m) | 14.29× |
| 2020-09-30 | $257.98M | $39.53M | $88.99M | $159.57M | $2.44M | (m) | $5.09M | (m) | 6.53× |
| 2020-06-30 | $249.58M | $33.72M | $21.59M | $221.10M | (m) | (m) | $2.43M | (m) | 7.40× |
| 2020-03-31 | $270.20M | $33.17M | $36.11M | $226.73M | (m) | (m) | $3.02M | (m) | 8.15× |
| 2019-12-31 | $290.88M | $32.81M | $9.21M | $271.66M | (m) | (m) | $4.56M | (m) | 8.86× |
| 2019-09-30 | $199.66M | $29.40M | $12.14M | $178.38M | $59.33K | (m) | $2.28M | (m) | 6.79× |
| 2019-06-30 | $163.26M | $20.95M | $11.34M | $147.83M | (m) | (m) | $1.41M | $71.50K | 7.79× |
| 2019-03-31 | $179.74M | $20.60M | $28.79M | $146.18M | (m) | (m) | $1.56M | $113.41K | 8.72× |
| 2018-12-31 | $195.68M | $22.98M | $3.19M | $184.64M | $2.78M | (m) | $2.76M | $154.46K | 8.52× |
| 2018-09-30 | $95.52M | $19.85M | $6.19M | $83.60M | (m) | (m) | $1.30M | $194.67K | 4.81× |
| 2017-12-31 | $65.53M | $17.85M | $30.91M | $8.26M | $25.00M | (m) | $596.53K | $159.26K | 3.67× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |